# An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome

> **NCT02036853** · PHASE2 · COMPLETED · sponsor: **Adrian Lacy** · enrollment: 20 (actual)

## Conditions studied

- Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)

## Interventions

- **DRUG:** Triheptanoin

## Key facts

- **NCT ID:** NCT02036853
- **Lead sponsor:** Adrian Lacy
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-20
- **Primary completion:** 2019-06-30
- **Final completion:** 2019-06-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-01-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02036853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02036853, "An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02036853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*